Glucose-dependent insulinotropic polypeptide - a new link in the development of obesity

Glucose-dependent insulinotropic polypeptide - a new link in the development of obesity

Objective. Glucose-dependent insulinotropic polypeptide (GIP) as well as glucagon-like peptide-1 (GLP-1) is intestinal incretin hormone that stimulates insulin secretion in response to feeding. Much evidence of GIP contribution to obesity development has been found recently.Aim. The aim of the study...

Full description

Bibliographic Details
Main Authors:	Ekaterina Alekseevna Shestakova, Aleksandr Victorovich Il'in, Marina Vladimirovna Shestakova, Ivan Ivanovich Dedov
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2015-04-01
Series:	Ожирение и метаболизм
Subjects:	gip glp-1 obesity type 2 diabetes
Online Access:	https://www.omet-endojournals.ru/jour/article/view/7018

Similar Items

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
by: Isabella Zaffina, et al.
Published: (2023-02-01)

Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
by: Tomislav Bulum
Published: (2022-10-01)

Expression of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in the rat submandibular gland is influenced by pre- and post-natal high-fat diet exposure
by: Pornchanok Sangsuriyothai, et al.
Published: (2024-03-01)

Glucose-dependent insulinotropic polypeptide (GIP) and GIP receptor (GIPR) genes: An association analysis of polymorphisms and bone in young and elderly women
by: Gaurav Garg, et al.
Published: (2016-06-01)

Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway
by: Michishige Terasaki, et al.
Published: (2021-07-01)

Microbial changes from bariatric surgery alters glucose-dependent insulinotropic polypeptide and prevents fatty liver disease
by: Tien S. Dong, et al.
Published: (2023-12-01)

Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice
by: Bo Ahrén
Published: (2023-02-01)

Glucose metabolism and incretins level in morbidly obese patients and in patients after biliopancreatic diversion performed for morbid obesity
Published: (2014-03-01)

Glucose-Dependent Insulinotropic Polypeptide Plasma Level Influences the Effect of n-3 PUFA Supplementation
by: Joanna Goralska, et al.
Published: (2022-08-01)

GIP_HUMAN [22–51] Peptide Encoded by the Glucose-Dependent Insulinotropic Polypeptide (GIP) Gene Suppresses Insulin Expression and Secretion in INS-1E Cells and Rat Pancreatic Islets
by: Emily Pusch, et al.
Published: (2023-10-01)

Editorial: Incretin agonists in the treatment of obesity
by: Xiaodong Sun, et al.
Published: (2023-08-01)

G protein-coupled receptors and obesity
by: Alessandro Pocai
Published: (2023-12-01)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
by: Patrick J. Knerr, et al.
Published: (2022-09-01)

Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
by: Geke Aline Boer, et al.
Published: (2020-12-01)

GLP1 and GIP are involved in the action of synbiotics in broiler chickens
by: Pawel Antoni Kolodziejski, et al.
Published: (2018-01-01)

Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature
by: Lampros G. Chrysavgis, et al.
Published: (2024-03-01)

Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment
by: Maria Chiara Pelle, et al.
Published: (2021-12-01)

The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity
by: Ioannis G. Lempesis, et al.
Published: (2022-12-01)

Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice
by: Seun Akindehin, et al.
Published: (2024-05-01)

The Role of GLP-1, GIP, MCP-1 and IGFBP-7 Biomarkers in the Development of Metabolic Disorders: A Review and Predictive Analysis in the Context of Diabetes and Obesity
by: Malwina Jędrysik, et al.
Published: (2024-01-01)

Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
by: Bin Yang, et al.
Published: (2022-12-01)

Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity
by: Tiago Morais, et al.
Published: (2023-04-01)

The postprandial dynamics of gastroduodenal zone hormones in patients with metabolic obesity associated or not associated with type 2 diabetes
by: Elena Vital'evna Kirienkova, et al.
Published: (2015-12-01)

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
by: Sara Baldassano, et al.
Published: (2019-08-01)

Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms
by: Othman Al Musaimi
Published: (2024-02-01)

Incretin hormone responses to carbohydrate and protein/fat are preserved in adults with sulfonylurea‐treated KCNJ11 neonatal diabetes
by: Pamela Bowman, et al.
Published: (2023-12-01)

Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion
by: Van B. Lu, et al.
Published: (2021-03-01)

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
by: Ruili Yin, et al.
Published: (2022-05-01)

Tirzepatide: A Systematic Update
by: Imma Forzano, et al.
Published: (2022-11-01)

Roles of glucose‐dependent insulinotropic polypeptide in diet‐induced obesity
by: Yusuke Seino, et al.
Published: (2022-07-01)

Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
by: Joanna Michałowska, et al.
Published: (2021-01-01)

Anti-Incretin Gut Features Induced by Feed Supplementation with Alpha-Amylase: Studies on EPI Pigs
by: Kateryna Pierzynowska, et al.
Published: (2023-11-01)

Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males
by: Dorte B. Zilstorff, et al.
Published: (2024-03-01)

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
by: Bastin M, et al.
Published: (2019-09-01)

Increased postprandial glycaemia, insulinemia, and lipidemia after 10 weeks’ sucrose-rich diet compared to an artificially sweetened diet: a randomised controlled trial
by: Arne Astrup, et al.
Published: (2011-07-01)

Effects of Ingesting Both Catechins and Chlorogenic Acids on Glucose, Incretin, and Insulin Sensitivity in Healthy Men: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial
by: Aya Yanagimoto, et al.
Published: (2022-11-01)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
by: Qian Zhou, et al.
Published: (2023-10-01)

Pharmacoeconomic assessment of type 2 diabetes mellitus care on the base of Endocrinology Research Centre, Moscow
by: Ivan Ivanovich Dedov, et al.
Published: (2012-09-01)

GIP Receptor Antagonist, SKL-14959 Indicated Alteration of the Lipids Metabolism to Catabolism by the Inhibition of Plasma LPL Activity, Resulting in the Suppression of Weight Gain on Diets-Induced Obesity Mice
by: Nakamura T, et al.
Published: (2021-03-01)